TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan adds generic Detrol, HIV/AIDS drugs

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MYL $27.29 +$0.10

at close on THURSDAY

Daily Photo Galleries

Thursday, Nov. 29, 2012, 12:40 p.m.
 

Mylan Inc. said on Thursday that it had introduced a generic incontinence drug to the U.S. market and was selected by the South African government as a supplier of antiretroviral drugs.

Cecil-based Mylan has started selling Tolterodine Tartrate tablets, the generic version of Detrol, made by Pfizer Inc. Tolterodine Tartrate had U.S. sales of $61.5 million for the 12 months ended Sept. 30.

The company said the South African National Department of Health selected Mylan's Indian subsidiary to supply it with 31 percent of the 30 million units of HIV/AIDS drugs it will buy in a two-year period ending Dec. 31, 2014.

Mylan's share of the contract is valued at about $127.5 million.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 
 


Show commenting policy

Most-Read Stories

  1. Penguins add scoring depth by dealing for Maple Leafs’ Winnik
  2. Notre Dame President Hesburgh expanded school, improved academics, fought for civil rights
  3. Pirates willing to consider high salary to keep star McCutchen
  4. Finding perfect pairing for Ehrhoff key for Penguins
  5. Toyota Mirai to run on hydrogen fuel cells, widen green-vehicle divide
  6. Ex-Brewers star Hart hopes to prove to Pirates he still can play
  7. Record-breaking temps could make February the coldest one since 1979
  8. PennDOT, Pa. Game Commission give falcons new nest in Tarentum
  9. Kittanning’s Robb hoping for rematch with West Branch’s Maines in final
  10. Pirates sickened by pic of ‘Jihadi John’ wearing Bucs ball cap
  11. Oakmont hit-run probed